San Diego
Althea is expanding its San Diego operations with the construction of a 57,000-sf biological manufacturing facility. Supporting the production of highly potent active pharmaceutical ingredients (HPAPIs) and antibody drug conjugates (ADCs), the project will feature cGMP-compliant suites for bioconjugation, formulation, purification, and aseptic fill and finish. The facility will open in the second quarter of 2016 with full operations commencing in mid-2017. Althea, a subsidiary of Ajinomoto, is a pharmaceutical contract development and manufacturing organization (CDMO).
Source
